Camaro1093 Stocks!

[Hammer1]

CTLE ON WATCH HERE as its ENTERED INTO A 2.7TRILLION DOLLAR MARKET PLACE.....Hammer

[Hammer1]

EMYSF GOING GREEN HERE......Hammer

[Hammer1]

CTLE ON WATCH.....SIDEWAYS BREAK COMING.....Hammer

[Hammer1]

EYMSF HERE ON NICE CONTRACT.....Hammer

http://finance.yahoo.com/news/easymed-emysf-signs-chanel-international-153942109.html

[Hammer1]

CTLE just hanging on that LOWER BB......sick CHANNEL....Hammer

[Hammer1]

CTLE now 2X +++++++ on the DAILY VOL.....FIRST 2 HOURS......Hammer

[buccaneer1961]

Cellceutix Announces A Study Planned At The University Of Bologna Titled “A Multi-Center, Open-Label, Phase Ib Study Of Kevetrin With Cytarabine In Patients With Acute Myelogenous Leukemia (AML)” ; U.S. Patent Issued for Kevetrin, Cellceutix's p53 Anti-Cancer Compound

http://us2.campaign-archive2.com/?u=9ed1a6b082ae8962468007971&id=2da02fc081&e=21d7b9f078

BEVERLY, MA – January 7, 2013-- Cellceutix Corporation (OTCBB: CTIX) (the “Company”), a clinical stage biopharmaceutical company focused on discovering small molecule drugs to treat unmet medical conditions, including drug-resistant cancers and autoimmune diseases, is pleased to provide information on the planned upcoming European clinical trials for Kevetrin™, the Company’s flagship anti-cancer compound.

The clinical phase 1b trial is titled “A Multi-Center, Open-Label, Phase 1B Study of Kevetrin with Cytarabine in patients with Acute Myelogenous Leukemia (AML)”

The University of Bologna in Italy (the “University”) and The Italian Cooperative Study Group on Chronic Myeloid Leukemia (ICSG on CML) and Acute Leukemia (GIMEMA Group) are sponsoring the clinical trials. Cellceutix has been advised that the submission for approval for the clinical trials are on schedule and the trials are expected to begin during the first half of 2013.

“Kevetrin has garnered the attention of some of the world’s foremost authorities in oncology,” commented Dr. Krishna Menon, Chief Scientific Officer of Cellceutix. “The University of Bologna has a distinguished history as a European leader in cancer research with a particular expertise in the field of hematological cancers. We could not be more pleased that this institution sees the potential for Kevetrin as a new drug candidate for AML and look we forward to building upon this special relationship with this esteemed institution.”

Cellceutix also announced today that the United States Patent and Trademark Office (USPTO) awarded the Company U.S. Patent No. 8,338,454 B2, titled “Nitrile Derivatives and their Pharmaceutical Use and Compositions.” The patent was issued on December 25, 2012.

The patent covers pharmaceutical compositions comprising Kevetrin™, the Company’s novel anti-cancer compound currently being evaluated in clinical trials against advanced solid tumors. The patent also covers related compounds and compositions.

Dr. Paul Ginsburg, a member of the Company’s Scientific Advisory Board, wrote the patent. Dr. Ginsburg has held senior legal positions at some of the world’s leading pharmaceutical companies, including Pfizer, Inc., Merck, and Schering-Plough. Dr. Ginsburg is perhaps most well-known as the author of the patent covering Schering-Plough’s hugely successful product Claritin. Dr. Ginsburg recently retired from Pfizer Inc., where he served as Head of the New York Patent Department and worked on patent matters relating to several blockbuster products, including Viagra, and represented Pfizer on the intellectual property committees of the National Association of Manufacturers, the Chemical Manufacturers Association and the Biotechnology Industry Organization.

Cellceutix’s intellectual property law firm, Ladas & Parry, prosecuted the above referenced patent.


About Kevetrin™

As a completely new class of chemistry in medicine, Kevetrin™ has significant potential to be a major breakthrough in the treatment of solid tumors. Mechanism of action studies showed Kevetrin's unique ability to affect both wild and mutant types of p53 (often referred to as the "Guardian Angel Gene" or the "Guardian Angel of the Human Genome") and that Kevetrin strongly induced apoptosis (cell death), characterized by activation of Caspase 3 and cleavage of PARP. Activation of p53 also induced apoptosis by inducing the expression of p53 target gene PUMA. p53 is an important tumor suppressor that acts to restrict proliferation by inducing cell cycle checkpoints, apoptosis, or cellular senescence.

In more than 50 percent of all human carcinomas, p53 is limited in its anti-tumor activities by mutations in the protein itself. Currently, there are greater than 10 million people with tumors that contain inactivated p53, while a similar number have tumors in which the p53 pathway is partially abrogated by inactivation of other signaling components. This has left cancer researchers with the grand challenge of searching for therapies that could restore the protein's protective function, which Kevetrin appears to be doing the majority of the time.

The clinical trial, titled "A Phase 1, Open-Label, Dose-Escalation, Safety, Pharmacokinetic and Pharmacodynamic Study of Kevetrin (Thioureidobutyronitrile) Administered Intravenously, in Patients With Advanced Solid Tumors," is available at: http://clinicaltrials.gov/ct2/show/NCT01664000?term=cellceutix&rank=1

About Cellceutix

Headquartered in Beverly, Massachusetts, Cellceutix is a publicly traded company under the symbol "CTIX". It is an emerging bio-pharmaceutical company focused on the development of its pipeline of compounds targeting areas of unmet medical need. Our flagship compound, Kevetrin™, is an anti-cancer drug which has demonstrated the ability in pre-clinical studies to regulate the p53 pathway and attack cancers which have proven resistant to today's cancer therapies (drug-resistant cancers). Cellceutix also owns the rights to seven other drug compounds, including KM-133, which is in development for psoriasis, and KM-391 for the treatment of the core symptoms of autism. More information is available on the Cellceutix web site at www.cellceutix.com.

Safe Harbor Forward-Looking Statements

To the extent that statements in this press release are not strictly historical, including statements as to revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future financial conditions, future collaboration agreements, the success of the Company's development, events conditioned on stockholder or other approval, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made. Factors that may impact Cellceutix's success are more fully disclosed in Cellceutix's most recent public filings with the U.S. Securities and Exchange Commission.

Cellceutix Corp.
Leo Ehrlich
[phone]

[Hammer1]

CTLE NICE BIO......Hammer

http://ih.advfn.com/p.php?pid=nmona&article=55472590

[Hammer1]

MDFZF on watch. Hammer

[Hammer1]

MVTG TECH IS SWEET. Hammer

COMPANY SNAPSHOT
INVESTMENT HIGHLIGHTS

Mantra Venture Group Ltd.’s primary operating business is Mantra Energy Alternatives Ltd, a wholly owned subsidiary. Mantra’s mission is to become the world leader in the production of high value, carbon negative chemicals and fuels. Its ERC system will reduce the problem greenhouse gas carbon dioxide (CO2) and convert it into a series of valuable chemicals, a form of carbon capture and recycling (CCR). There are currently 27 billion metric tons of CO2 emitted annually from fossil fuel combustion, providing an inexhaustible supply of feedstock. Mantra’s first product is formic acid (HCOOH), which commands a market of approximately $1 billion.

[mlkrborn]

GALE looking good with patent rights!

[Cburg]

Has anyone tried the Wealth Advisor Report?
They are touting a bio that grows organs. Does anyone know what the company name is?
Here is an email:

Dear Energy and Capital Reader,

Take a look at this. You'll soon be seeing a lot more of it:



That's a mold to grow a human ear from scratch.

And the doctor who made it is on the board of a $3.00 biotech company that's about to commercialize the technology — and rake in billions in profits.

It's not just ears, though...

This new “tissue engineering” technology works for kidneys, bladders, tracheas, limbs, and more.

And it's been under the radar... until now.

Just this week, two major news outlets have reported on the doctor and his breakthrough. And as you can imagine, the news is quickly circling the Internet.

It's only a matter of time before millions of people learn about this new medical marvel, making this one of the best stocks of the decade.

To your wealth,



Brian Hicks
Publisher, Energy and Capital

http://www.angelnexus.com/o/web/25503

Thanks!
Mike

[Camaro1093]

XNPT (XenoPort) is looking like a great run-up play into their 4/6/11 PDUFA.

[Camaro1093]

BioShockers Alert

Added to my $INHX position @ $2.67.

[Camaro1093]

BioShockers Alert

Out $CAPS @ $1.17-$1.19 from $0.92 entry two weeks ago. Congrats to all who own this one..

[TH_Stockhunter]

Saw that! The $heff-effect is on it!

[Camaro1093]

$CAPS on fire - up almost 20%

[Camaro1093]

$CAPS - huge volume today (162k).

[Camaro1093]

$CAPS - news. Data will be released Tuesday...

PR LINK:

http://finance.yahoo.com/news/Capstone-Therapeutics-to-Host-pz-1693787737.html?x=0&.v=1

[Camaro1093]

Sorry I haven't been on the board - been really busy working on the site (BioShockers.com), and twitter.

Will start posting again on the board here, though. :)

[Camaro1093]

BTW, got your PM - couldn't reply, though. IMO, the best way to bring attention to the board would be to put a link to it in your signature.

[TH_Stockhunter]

CYTK - will be presenting data in December at a Major ALS (Lou Gehrig’s Disease) conference from Dec 11th-13th. This Phase II data will be a significant milestone for the company. They have already conducted two interim analyses from this trial both of which produced encouraging pharmacodynamic trends they the hope will be substantiated and supported in the final data to be presented.
CK-2017357 is currently the subject of a Phase IIa clinical trials program and has been granted orphan-drug designation by the U.S. Food and Drug Administration for the potential treatment of amyotrophic lateral sclerosis.

Data Ph2a Amyotrophic lateral sclerosis at 21st International Symposium on ALS/MND Dec 11-13

52 wk low is $2.03 and 52 wk high is $3.78.

[Camaro1093]

Very nice! I almost bought that one, but Etrade has it limited to call-in only orders.

[TH_Stockhunter]

Currently holding CYTK (2.80), got in at 2.49 on monday! Stock is on a breakout! Broke 200dma at 2.71 today!

[Camaro1093]

$CAPS looks great today.. Phase 2a data coming out any day now... Holding my position @ $0.92...

[Camaro1093]

BioShockers Alert

Bought more $INHX @ $2.77.

[Camaro1093]

We now have 310 followers on Twitter: www.twitter.com/BioShockers

[Camaro1093]

FDA Calendar: http://bioshockers.com/?page_id=4

[Camaro1093]

Awesome move on Orexigen - had a small position - sold my $5.50 shares after-hours yesterday @ $12.20. :)

[Camaro1093]

$ARIA - phase 3 data coming out ~1Q 2011. Partnered w/ Merck. Have $102M in cash. Really solid company here.

[Camaro1093]

BioShockers Alert

Bought $ARIA @ $3.51.

[Camaro1093]

ENMD moving today - $6.60.

[Camaro1093]

Huge news on AMRN today... Sold my shares @ $4.13 (way too early, but still a nice profit).

[TH_Stockhunter]

SNSS: Here is why this stock has so big potential:

1. First they have to have the BID over $1 for 10 consecutive days by march 2011 to keep NASDAQ listing, which I am very sure they want to maintain!

2. They have 2 drugs in phase 2 which could go to phase 3.

3. They are in the sweet spot of cancer research

Look at the pipeline!
http://www.sunesis-pharma.com/products-in-development/

4. Last year at this time, the stock ran from .40 to $2.32 on good results!

5. Chart primed for a run! Bottomed at .29 and friday it traded up 10% on 2x the 20day MA for vol.

6. Big institutional holdings!

[TH_Stockhunter]

Bioshockers alert: Bought shares of SNSS @ .367! Stock closed @ .375 +10% and traded up to .40 in after-market! Stock has serious potential for a big move up..

[Camaro1093]

Bought some ENMD today in the $5.30s... One of my favorite biotech stocks..

[Camaro1093]

I've heard quite a bit about REE recently.. I'll check it out, thanks for the tip! :)

[TH_Stockhunter]

AVNR Approval friday - now $5.50 HOD +126% pre-market!!!

[greggor62]

I have been wayching REE Rare element it has been on a tear, Looks like it"s getting ready for next leg up.
Everything elsce is in C citigroup. Biggest no brainer in the market. I am learning patients pays off.
Had some nice fishing this season. picked up a little boston whaler. had a blast with it.
Hope all is well. Check out REE
Peace

[Camaro1093]

Canaccord Genuity reiterates a 'Buy' on Avanir Pharmaceuticals (Nasdaq: AVNR), raises PT from $6 to $9.

Canaccord analyst says, "...Raising target to $9 based on higher chances of FDA approval on Oct. 30 PDUFA, long-term commercial success. We raised our estimate of approval chances for AVNR’s lead drug AVP-923 for PBA from 60% to 75% based on extensive talks with experts and new safety detail. Expert opinion on 923 safety and efficacy has been very positive. We think AVNR will drive strong PBA awareness and conduct a strong launch in Q1/11. We think 923 will see good market uptake starting in H2/11."

To see all the upgrades/downgrades on shares of AVNR, visit our Analyst Ratings page.

Shares are trading at $3.33, up $0.18 (+5.71%) today.

[Camaro1093]

Still holding onto your AVNR? I closed out a small portion of my position today @ $3.38 to lock in profits, I'm probably going to hold the rest of it through approval.

[Camaro1093]

My summer was pretty good, but this Fall is looking much better trading-wise

[greggor62]

Hey, how was your summer? Had a good one myself. Busy hanging on to what I got. No room to gamble. lol
How are you fairing? Hope all is well, and you are making some good trades.
Gorggor

[TH_Stockhunter]

AVNR ($3.42) looking really good! I like the continued uptrend on high volume! $3.50 a possibility today! IMO

[Camaro1093]

Yeah, lots of volume today too (currently 1.26M).

[TH_Stockhunter]

AVNR ($3.04) looking really good today! Broke $3 resistance and would be great to close above that! Multiweek runner up to Oct. 30 PFUDA date! IMO

[Camaro1093]

AVNR currently holding @ $2.91

[Camaro1093]

Nice buy! I did the same thing, got in at $2.92.

[Camaro1093]

Thanks!

[TH_Stockhunter]

Bioshockers alert

Took a position in AVNR here at $2.87, hoping for a run-up to PFUDA date Oct. 30th and approval of the drug!